phase pharmacokinet trial intraperiton etoposid combin multidrug-resistance-modul agent dipyridamol dipyridamol sensit human ovarian carcinoma cell vitro phase trial feasibl dipyridamol sensit tumor periton caviti etoposid dipyridamol continu intraperiton infus patient maximum dose etoposid day dipyridamol fix dose day dose-limit toxic effect leukopenia thrombocytopenia major toxic effect free periton etoposid dipyridamol concentr etoposid dose rate microm etoposid dose rate day free etoposid dipyridamol concentr rang synergist interact 